Bayer Eylea 8 mg approved in EU for treatment of two major retinal diseases
The article discusses the approval of Bayer Eylea 8 mg in the European Union for the treatment of two major retinal diseases. This medication is used to treat neovascular (wet) age-related macular degeneration and visual impairment due to diabetic macular edema. The approval allows for the use of a higher dose of Eylea, providing potential…